The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Recently approved treatments and updates to genetic testing recommendations for prostate cancer have created a need for correlated analyses of patient outcomes data via germline genetic mutation status. Genetic registries address these gaps by identifying candidates for recently approved targeted treatments, expanding clinical trial data examining specific gene mutations, and understanding...
This paper studies the dynamic performance of an electric machine integrated with the trans-rotary magnetic gear (MITROMAG) in a motoring mode of operation. MITROMAG is formed by mechanically coupling a rotary electric machine to the rotor of a trans-rotary magnetic gear (TROMAG). TROMAG is a magnetic device that converts low-torque, high-speed rotation of its rotor to a high-force, low-speed linear...
This work presents a proposed design of a fuzzy logic-controlled hybrid transmission with only one electric motor/generator (MG) and without any rotating clutches. The proposed hybrid transmission serves to regulate the engine's effective gear velocity by mixing the engine and electric MG powers through a power controlling device. With a control unit, four major modes of operation excluding a regenerative...
Hormone-refractory prostate cancer (HRPC) encompasses a wide spectrum of patients, including patients with prostate-specific antigen (PSA)-only disease, those with increasing PSA levels yet stable metastatic disease, and those with increasing PSA levels and objective evidence of progressive metastases. Unfortunately, with the historical lack of effective therapy in this population, the oncologist...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.